The scientific evidence: Vildagliptin and the benefits of islet enhancement

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 2, 2009, Pages 9-17

  Mathieu, Chantal ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Incretins; Islet enhancement; Vildagliptin; cell function

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METFORMIN; PLACEBO; VILDAGLIPTIN;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REVIEW;

EID: 65449151804     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01033.x     Document Type: Review

References (24)

1. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-295.
2. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
3. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
4. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
5. He Y-L, Wang Y, Bullock JM et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007; 47: 633-641.
6. Ristic S, Bates PC. Vildagliptin: A novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. Drugs Today 2006; 42: 519-531.
7. Henness S, Keam SJ. Vildagliptin. Drugs 2006; 66: 1989-2001.
8. Ayalasomayajula SP, Dole K, He Y-L et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007; 23: 2913-2920.
9. He YL, Sabo R, Sunkara G et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007; 47: 998-1004.
10. He YL, Sabo R, Riviere GJ et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131-1138.
11. He YL, Ligueros-Saylan M, Sunkara G et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008; 48: 85-95.
12. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
13. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008; 93: 103-109.
14. Scherbaum WA, Schweizer A, Mari A et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 1114-1124.
15. Ahrén B, Schweizer S, Dejager S et al. Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes. Diabetologia 2008; 51(Suppl. 1): S36-S37. Abstract 75.
16. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
17. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298: 779-784.
18. Hinke SA, Kühn-Wache K, Hoffmann T et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
19. Migoya E, Miller J, Larson P et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetologia 2007; 50(Suppl. 1): S52. Abstract 0111.
20. Dunning BE, Ligueros-Saylan M, D'Alessio DA et al. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naïve and metformin-treated patients with type 2 diabetes. Diabetologia 2006; 49(Suppl. 1): 110-111. Abstract 0174.
21. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
22. Azuma K, RádikováZ, Mancino J et al. Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 459-464.
23. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
24. Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes. Diabetes 2007; 56: 1475-1480.